Flavay™
protects the blood platelets without an
increased risk of bleeding
and other common side effects of aspirin.
Licensed
and sold for cardiovascular health
in France for more than 50 years,
the vascular protective activity
of Flavay™ has been established
by many significant studies.
MORE
|
When we are
under stress, our adrenaline flows and
causes our blood vessels to constrict,
increasing blood pressure, and blood
platelets are activated—prepared to clump
together to form a clot. This "fight or
flight response" is appropriate in
short-term dangerous situations. The blood
platelets are prepared for an injury to more
quickly form a blood clot and more
efficiently prevent blood loss.
Chronic
stress causes constant constriction of blood
vessels and continuously "sticky"
blood platelets, always prepared to form a
clot. These are classic risk factors for
heart disease and stroke. When blood vessels
are constricted there is less area for the
blood to flow through and atherosclerotic
plaque may further reduce the space for
blood flow. If some blood platelets stick
together and form a clot, the vessel may be
completely clogged and surrounding tissue is
deprived of oxygen and nutrients. This is
how a heart attacks and strokes develop.
Flavay™
improves nitric oxide
levels which causes blood
platelets to return to their
normal, smooth condition.
|
Research
shows that Flavay™ improves nitric oxide
levels produced by cells that line the
arteries. Nitric oxide controls the muscles
surrounding the blood vessels and causes
them to relax. At the same time, nitric
oxide causes blood platelets to return to
their normal, smooth condition.
Flavay™
inhibits platelet aggregation by inhibiting
the enzymes thromboxane A2, 5-lipoxygenase
and other clotting compounds. The good news
is that Flavay™ protects the blood
platelets without an increased risk of
bleeding and other common side effects of
aspirin.
Aspirin is
widely prescribed by doctors to prevent
heart attacks because of its ability to
inhibit platelet aggregation by inhibiting
the enzyme cyclooxygenase. However, Flavay™
works differently. Flavay™ supports the
body's own production of nitric
oxide—helping the body to produce adequate
levels and thereby causing the blood
platelets to return to their normal, smooth
condition.
Flavay™
and the Nitric Oxide Connection
Nitric
oxide is a colorless gas produced by
different cells in the body that, depending
on the situation, can be very good
or very bad. Nitric oxide plays
several important roles in the body:
- Nitric
oxide is an important signaling
molecule that turns genes on and off.
- By
controlling the muscular tone of blood
vessels, nitric oxide regulates the
circulation and normalizes blood flow.
- Nitric
oxide modulates communication between
brain cells and is instrumental in
helping us concentrate and learn new
information, and also in maintaining
memory.
- When
produced by immune cells, nitric oxide
fights infection, kills tumor cells
and promotes wound healing.
- Nitric
oxide is essential for perceiving
pleasure and pain, and it helps
translate sexual excitement into
penile erections.
- Nitric
oxide aids in digestion of food by
helping to control gastric movements.
But nitric
oxide can be very destructive under other
circumstances:
- Nitric
oxide restricts blood flow.
- When
produced in excess by immune cells,
nitric oxide can trigger chronic
inflammation, which can cause
arthritis, colitis, inflammatory bowel
disease and possibly cancer.
- Nitric
oxide promotes production of more free
radicals.
- In the
brain, nitric oxide can hamper mental
function and cause memory loss and
brain aging.
The real
trouble starts when nitric oxide encounters
the superoxide free radical and becomes
peroxynitrate, which destroys antioxidants
like glutathione, vitamin E and common
flavonoids, and damages proteins in the
body. The good news is that Flavay™
scavenges peroxynitrate and has a remarkable
modulatory effect on nitric oxide—helping
to maintain optimal levels in the body and
neutralizing this free radical where it does
harm.
"Radical
Scavenger Effect" of Flavay™
Protected by U.S. Patent No. 4,698,360
Patented
and licensed in France for therapeutic uses,
the U.S. Government granted Dr. Masquelier a
patent on October 6, 1987 which allows his
proanthocyanidins complex, now sold as
Flavay™, to be used as an antioxidant here
in the United States.
|
"[A]
method for preventing and
fighting the harmful biological
effects of free radicals in
the organism of warm blooded animals
and more especially human beings,
namely cerebral involution, hypoxia
following atherosclerosis, cardiac
or cerebral infarction,
tumour promotion, inflammation,
ischaemia, alterations of the
synovial liquid, collagen
degradation, among others.
The method consists in administering
to said animals and especially to
human beings an amount, efficient
against said effects, of a plant
extract with a proanthocyanidins
content which has a radical
scavenger effect"—Dr.
Jack Masquelier, U.S. Patent No.
4,698,360.
|
Flavay™
is the product—used in the
actual experiments—by which
Dr. Jack Masquelier established
and patented the "Radical
Scavenger Effect."
|
Flavay™
has been sold world-wide for cardiovascular
health and extensively tested in humans for
more than 50 years. The vascular protective
activity of Flavay™ has been established
by many significant studies, demonstrating
several important ways in which Flavay™
may mitigate the risk of heart attack and
stroke. MORE
 CLICK
HERE FOR AN INDEPENDENT LAB REPORT
|
|
All About Flavay
| Flavay Plus | What Does
it Do? | Proven Safety
| Directions for Use
Q&A | Comparative Analysis | Endorsements & Testimonials
| How to Purchase
HealthyBodynMind
1-877-352-8042 • (306) 352-8042 • info@healthybodynmind.com
Protected by U.S. PATENT NO. 4,698,360 and international
patents.
Copyright © 1995-2004 Healthy Publisher.
All rights reserved. Healthy Source LLC
|
Statements made herein have not been
evaluated by the Food and Drug Administration. These products are
not intended
to diagnose, treat, cure or prevent any disease.
|
REFERENCES:
Top  |
Masquelier, J. Plant extract with
a proanthocyanidins content as a therapeutic agent having radical scavenging
effect and use thereof. U.S. Patent No. 4,698,360, 1987.
Masquelier, J. A lifetime devoted to OPC and
Pycnogenols. Alfa Omega
Editrice,
Pub., 1996.
Schwitters, B.,
Masquelier, J. OPC in practice. Alfa Omega
Editrice, Publishers,
1995.
Lombard, J., Germano, C. The brain wellness plan: breakthrough medical,
nutritional and immune-boosting therapies to prevent and treat: depression,
Alzheimer's disease, chronic fatigue syndrome, attention deficit disorder,
multiple sclerosis, Parkinson's disease, Lou Gehrig's disease. Kensington
Pub. Corp., 1998.
Kilham, C., Masquelier, J.
OPC: The miracle antioxidant. Keats Publishing,
Inc., 1997.
Packer, L., et al. The antioxidant miracle: your complete plan. John Wiley
& Sons, Inc., 1999.
Packer, L., et al. Antioxidant food supplements in human health. Academic
Press, 1999.
Lincoln, J., Hoyle, C.H.V., Burnstock, G., Nitric oxide in health and
disease. Cambridge University Press, 1997.
Moncada, S., Nistico, G.,
Bagetta, G., Higgs,
E.A. Nitric oxide and the
cell. Princeton University Press, 1998.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme activities
of procyanidines from vitis vinifera. A mechanism for their capillary
protective action. Arzneimittelforschung, 44: 592-601, 1994.
Passwater, R.A. The antioxidants: the nutrients that guard your body.
Keats Publishing, Inc., 1985.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants.
Keats Publishing, Inc., 1995.
Facino RM, et al. Free radical scavenging action and anti-enzyme activities
of procyanidines from Vitis vinifera. A mechanism for their capillary
protective action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant to the
action of mammalian collagenase. Experientia, 37: 221-223, 1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres
procyanidoliques.
Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains
flavonoides.
A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques
totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres
flavonoliques.
Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action des
oligomeres procyanidoliques sur des cellules mesenchymateuses en culture.
Ii l’attachment des fibres elastiques aux cellules. (Study of the
effect of procyanidolic oligomers on mesenchymal cells in culture. Ii
attachment of elastic fibers to the cells.) Pat Biol, (30)6:601-7, 1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and
crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3’,
4.4’, 5.7’-Hexahydroxyflavan] dihydrate, and comparison of its
heterocyclic ring conformation in solution and the solid state. Journal
of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux
libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free radicals.
Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and
b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990.
pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different procyanidins
from grape seeds. Presented at a symposium, “Free radicals in biotechnology
and medicine.” Royal Society Of Chemistry, London January 1990, pp.
79-80.
Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase
durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften”
Arch Pharm, (Weinheim) 313 (1980) pp. 330-337.
Flesch M., et al., Effects of red and white wine on endothelium-dependent
vasorelaxation of rat aorta and human coronary arteries. Am J Physiol
1998;275:1183-94.
Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM. Isolation
and characterization of endothelium-dependent vasorelaxing compounds from
grape seeds. J Agr & Food Chem In press.
Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation, endothelium,
and wine. BioFactors 1997;6:455-459.
Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey RG. Endothelium-dependent
vasorelaxation caused by various plant extracts. J Cardiovasc Pharmacol
1995;26:90-95.
Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing
activity of wine and other grape products. Amer J Physiol 1993;265:H774-H778.
Kuttan, R., Donnelly,
P.V., Di Ferrante, N. Collagen treated with catechin
becomes resistant to the action of mammalian collagenase. Experientia,
37: 221-223, 1981.
Masquelier, J. Procyanidolic
oligomers. J Parums Cosm
Arom, 95: 89-97,
1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies that binding
of pycnogenols to elastin affects its rate of degradation by elastases.
Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem.
Pharm. Bull. 33:5079, 1985.
Harmand, M.F.,
Blanquet, P. The fate of total flavanolic oligomers extracted
from ‘vitus vinifera l.’ in the rat. European Journal of Drug
Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30.
Delrieu, P., Ding J.,
Escande, B., Samain, D. Free-radical scavenging
activity of proanthocyanidolic oligomers encapsulated in glycospheres:
an in vivo and in vitro study. Cosmetology Department & S Biovectors,
Ramonville St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting
enzyme by flavanolic compounds: in vitro and in vivo studies. Planta
Medica,
May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-activite aniagoniste vis-a-vis des mediateurs de l’inflamation.
Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G.,
Hugonot, H. Evolution de la resistance
capillaire,
spontanement ou artificiellement diminuee par l’action d’une
substance capillaro-toxique chez des personnes agees--action benefique
d’un agnet actif sur la micro-circulation: l’Endotelon. Inform.
Therapeut. 1980. pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude d’un
microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990.
Lagrue, G., Olivier-Martin, F.,
Grillot, A. “Etude des effets des
oligomeres du procyanidol sur las resistance capillaire dand l’hypertension
arterielle et certaines nephropathies.” Sen. Hosp. Paris 18-25
Septembre,
1981.
Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur
peripherique, l’Endotelon. Actualite Therapeutique
Gaz. Med. de France
(87)22:2919-24, 1980.
Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice
de fragilite capillaire dan une population specifique: les sujets
cirrhotiques. Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres inferieurs
par un microangioprotecteur l’Endotelon. Bordeaux Med, 11:685-8,
1981.
Delacroix, P. Etude en double aveugle de l’Endotelon dans l’insuffisance
veineuse chronique. Therapeutique, la Revue de Medicine, (27-28) Sept.
1981. pp. 1793-1802.
Thebaut, J.F, Thebaut, P.,
Vin, F. Etude de l’Endotelon dand les
manifestations fonctionnelles de l’insuffisance veineuse peripherique-resultats
d’une etude en double aveugle portant sur 92 patients.” Gazette
Medicale, (92)1, 1985. pp. 96-100.
Wegrowski, J., Robert, A.M.,
Maczar, M. The effect of procyanidolic oligomers
on the composition of normal and hypercholesterolemic rabbit aortas.
Biochem. Pharmacol, (33)21. 1984. pp. 3491-3497.
Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and arachidonate
metabolism in platelets by procyanidins. Prostagland Leukotri Essent Fatty
Acids, 38:181-8, 1989.
Masquelier, J.
Pycnogenols: recent advances in the therapeutical activity
of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant
Research and Journal of Natural Products, July 1980 pp. 243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury: implications
in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106.
Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.”
pp. 88-93.
Gazave, J.M. “Notions recentes sur les capillaires”
unpub. bulletin
from the Laboratoire De Physiologie Patholigie pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation and
atherothrombosis.
Office International Vigne et du Vin, Nutrition and Health Unit, Paris
France; Drugs under Experimental and Clinical Research (Switz.) 25/2-3
(125-131), 1999.
Blaszo, G. Gabor, M.
Oedema-inhibiting effect of
procyanidin. Acta Physiologica
Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase.
Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en
gynecologie. Essai
Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P “Une Etude Exemplaire Pour Un
Phlebotrope: l’etude
EIVE.’ Unpub., pp. 77-83.
Pfister, A., Simon,
M.T., Gazave, J.M. Sites de fixation des oligomeres
procyanidoliques dans la paroi des capillaires sanguins du poumon
decobaye.
Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di
Ferrante, N. “Collagen treated with
(+) -catechin becomes resistant to the action of mammalian collagenase.”
Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col.
of Med., Houston TX. 28, May, 1980.
Gendre, P., Laparra, J.,
Barraud, E. “Effect protecteur des oligomeres
procyanidoliques sur le lathyrisme experimental chez le rat.” Ann.
Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P.,
Siou, A. Light vision and chorioretinal circulation.
Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr.
Opthalmol,
(11)5:453-460, 1988.
Boissin, J.P., Corbe C.,
Siou, A. Chorioretinal circulation and dazzling:
use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4,
177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside
oligomers effects on retinal function in myopic subjects. Ann Ott Clin
Ocul, 114:85-93, 1988.
Saracco, J.B., Estachy,
G.M. Etude d l’Endotelon en
opthalmologie.
Gaz Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies.
Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr.
Opthalmol, 11:453,
1988.
Verin, M.M., Vildy, A.,
Maurin, J.F., Retinopathies et
O.P.C. Bordeaux
Medicale, (16)11. pp. 1467-74, 1978.
Soyeux, A. et al.
Endotelon. Diabetic retinopathy and
hemorheology. Bull
Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. “Les oligomeres procyanidoliques dans le traitement
de la fragilite capillaire et de la retinopathie chez les diabetiques.
A propos de 26 cas.” Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques:
Endotelon, dans la retinopathie diabetique (a propos de 30 observations).
Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results of a double-blind
study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5,
1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism
in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels.
Angiologica,
9:355-374, 1972.
Havsteen, B.
Flavonoids, a class of natural products of high pharmacological
potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J.
Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977.
Masquelier, J. Action protectrice du vin sur l’ulcere
gastrique. Resultats, p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by flavonoids
and bioflavonoids. Planta Medica, 5116-20, 1985.
Shaw, R. How [Australian] PycnoGenol [MASQUELIER’s®] Helps Sports
People.
Masquelier, J. Procyanidolic oligomers
(leucocyanidins). Parfums Cosmet
Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques
(Endotelon) dans le traitement des lymphoedemes
post-therepeutiques de
members superieurs. Symposium Satellite, Congres International d’Angiologie,
Toulouse, France, 4-7 Oct. 1989. |
|
